key: cord-0998009-8f3kumw0 authors: Egilmezer, Ece; Rawlinson, William D title: Review of studies of severe acute respiratory syndrome related coronavirus–2 pathogenesis in human organoid models date: 2021-03-25 journal: Rev Med Virol DOI: 10.1002/rmv.2227 sha: a23314924bfcfc44bd0d771c4b1d0db5e62b25da doc_id: 998009 cord_uid: 8f3kumw0 Severe acute respiratory syndrome related coronavirus‐2 (SARS‐CoV‐2) is the cause of Covid‐19 which was classified as a global pandemic in March 2020. The increasing global health and economic burden of SARS‐CoV‐2 has necessitated urgent investigations into the pathogenesis of disease and development of therapeutic and vaccination regimens. Human trials of vaccine and antiviral candidates have been undertaken, but basic pathogenetic studies are still required to inform these trials. Gaps in understanding of cellular infection by, and immunity to, SARS‐CoV‐2 mean additional models are required to assist in improved design of these therapeutics. Human organoids are three‐dimensional models that contain multiple cell types and mimic human organs in ex vivo culture conditions. The SARS‐CoV‐2 virus has been implicated in causing not only respiratory injury but also injury to other organs such as the brain, liver and kidneys. Consequently, a variety of different organoid models have been employed to investigate the pathogenic mechanisms of disease due to SARS‐CoV‐2. Data on these models have not been systematically assembled. In this review, we highlight key findings from studies that have utilised different human organoid types to investigate the expression of SARS‐CoV‐2 receptors, permissiveness, immune response, dysregulation of cellular functions, and potential antiviral therapeutics. Severe acute respiratory syndrome related coronavirus-2 (SARS-CoV-2) is the cause of Covid-19 which was classified as a global pandemic in March 2020. The increasing global health and economic burden of SARS-CoV-2 has necessitated urgent investigations into the pathogenesis of disease and development of therapeutic and vaccination regimens. Human trials of vaccine and antiviral candidates have been undertaken, but basic pathogenetic studies are still required to inform these trials. Gaps in understanding of cellular infection by, and immunity to, SARS-CoV-2 mean additional models are required to assist in improved design of these therapeutics. Human organoids are three-dimensional models that contain multiple cell types and mimic human organs in ex vivo culture conditions. The SARS-CoV-2 virus has been implicated in causing not only respiratory injury but also injury to other organs such as the brain, liver and kidneys. Consequently, a variety of different organoid models have been employed to investigate the pathogenic mechanisms of disease due to SARS-CoV-2. Data on these models have not been systematically assembled. In this review, we highlight key findings from studies that have utilised different human organoid types to investigate the expression of SARS-CoV-2 receptors, permissiveness, immune response, dysregulation of cellular functions, and potential antiviral therapeutics. the Middle Eastern respiratory syndrome related coronavirus (MERS-CoV), and recently SARS-CoV-2. 2,4,5 Covid-19 is caused by SARS-CoV-2 infection and was classified as a pandemic by the World Health Organisation (WHO) in March 2020. 6 The symptoms of Covid-19 range widely, presenting as asymptomatic in many individuals or fever, myalgia, cough, chest tightness, and in severe cases pneumonia, occasionally resulting in death. 7 The current pandemic has developed globally rapidly, meaning there is urgency around studies of the pathogenetic mechanisms of SARS-CoV-2 infection to inform development of antiviral drugs and vaccines. A key method of investigating pathogenesis of infection, assisting design and development of therapeutics, is the employment of three-dimensional, multi-cell-type culture models known as orga- Two-dimensional cell monocultures and animal models are frequently used to model human viral infections. Monocultures are the primary model used in the isolation and propagation of viruses, including the first culture of SARS-CoV-2 in the Vero/hSLAM cell line. 8 However, monocultures do not accurately represent the complexity of in vivo tissues. Different cell types in organs, such as the brain, have specific gene regulation patterns which would otherwise not be taken into account in single-cell culture models. 9, 10 This has been further confirmed by reported alterations in cell signalling networks between two-and three-dimensional culture systems. 11, 12 In order to overcome these limitations, researchers have begun utilising alternative three-dimensional disease modelling systems, such as organoids. These more closely mimic the complex multi-cell-type composition and structure of human organs. 13, 14 Animal models are multi-cell-type, multi-organ models that facilitate the translation from basic research to clinical trials. Animal models are essential in informing the development of antiviral treatments and vaccines and have recently been used to evaluate Covid-19 vaccine candidates in models such as Rhesus macaques. [15] [16] [17] However, the differing developmental patterns between non-human animals and humans 18 have necessitated the development of alternative human organ models such as organoids. Furthermore, the ethical considerations involved in animal research are monitored through the 3Rs principle (replacement, reduction and refinement of animal research) in an effort to maximise highquality data while minimising harm to animals during research. 19 This principle dictates the replacement of animal models where possible through the use of alternative culture systems such as human organoids. 20 Organoids are organ-like tissue models from pluripotent stem cells or progenitor cells through differentiation. 13 During the differentiation process, multiple cell types arise and self-organize to form cellular organisation and tissue morphology resembling in vivo human organs, which can be used to model infection. 13, 14 Organoids have successfully been used to model neurological infections such as with Zika virus (ZIKV). 21 Congenital ZIKV infection has been associated with the development of foetal neural malformation such as microcephaly. 22 Researchers have utilised cerebral organoids to study pathogenesis of ZIKV infection, including brainregion-specific forebrain organoids. 21 In this model, ZIKV induced increased cell death and reduced cellular proliferation, subsequently decreasing neuronal volume, inducing microcephaly-like pathophysiology, 21 suggesting a mechanism for ZIKV-induced neural malformation. Different organoids have been utilised in SARS-CoV-2 mechanistic investigations. The respiratory tract is the major organ system affected by Covid-19 disease, although injury to other organs has been observed including acute kidney injury, cardiovascular disease and neurological disease including encephalopathy, encephalitis, Guillain-Barre syndrome and acute stroke. 23, 24 The wide array of organs affected in Covid-19 disease necessitates the use of a variety of organoid models to extrapolate the mechanisms of SARS-CoV-2 infection in different systems. Specific growth and differentiation factors that facilitate the development and generation of a variety of organoids have been used to produce organoids simulating different human organs, allowing a biologically relevant, three-dimensional model for disease. 13, 14 In this review, we detail the conclusions drawn from 16 studies investigating SARS-CoV-2 infection of different human organoid models. Investigating the presence of these host cell receptors in various organoid models is an important first step in determining their ability to support viral infection. The detection of these receptors in various organoids is summarised in Figure 1 . In organoids, the ACE2 receptor was detected in lung (pre-print), 31,32 bronchial (pre-print), 33 the choroid plexus, 34 hippocampus, 34 brain, 35 self-formed ectodermal autonomous multizone (SEAM) eye (pre-print), 36 intestinal enteroids, 37,38 colonic, 32 kidney 39,40 and liver 41, 42 organoids, as well as brain spheres. 43 Interestingly, ACE2 was also expressed in multipotent neural progenitor cells (NPCs), from which brain spheres are generated through differentiation. 43 During foetal cerebral organogenesis, NPCs are a crucial population of cells, with the capability of differentiating into oligodendrocytes, astrocytes and neurons that populate the developed adult brain. 44, 45 The presence of the ACE2 receptor in this population of cells suggests SARS-CoV-2 tropism, and further research is required to determine the effects of infection on foetal brain development. However, most guidelines suggest effects on the foetus are unlikely (UK guidelines). 24, 46 The TMPRSS2 receptor was expressed in lung (pre-print), 31, 32 bronchial (pre-print), 33 choroid plexus, 34 hippocampal, 34 SEAM eye (pre-print), 36 intestinal enteroid, 37 colonic 32 and liver 41 organoids. However, TMPRSS2 receptor expression was reportedly below the limit of detection in brain spheres. 43 Expression of these target cellular receptors localised in certain cell populations in organoids. In lung organoids, ACE2 was detected predominantly in club 31 and TMPRSS2 are expressed in the basal cells of bronchial organoids, but only TMPRSS2 is expressed in ciliated cells (pre-print). 33 Single-cell RNA sequencing of SEAM eye organoids revealed ACE2 may be predominantly expressed in the limbus, conjunctiva and a subset of ocular surface ectoderm cells (pre-print). 36 The TMPRSS2 receptor was expressed in corneal cells in SEAM eye organoids (pre-print). 36 Single-cell profiling of kidney organoids revealed the proximal tubule and podocyte II cell clusters express ACE2. 39 Organoids have allowed researchers to identify specific cell populations that express SARS-CoV-2 receptors in the lung, [31] [32] [33] eye 36 and kidney. 39 Understanding the localisation and enrichment of host cell receptors that are utilised by SARS-CoV-2 during infection not only indicates the cell types that are more permissive to infection in specific organs, but also can potentially inform development of targeted therapeutics to these vulnerable cell populations. Severe acute respiratory syndrome related coronavirus-2 (SARS-CoV-2) and host cell receptors. (a) Viral attachment and cellular entry is mediated by the SARS-CoV-2 spike (S) protein. The N-terminal subunit, S1 binds to the receptor, angiotensin I converting enzyme 2 (ACE2). [25] [26] [27] Hoffmann et al. suggest the S protein is primed by the transmembrane serine protease 2 (TMPRSS2), inducing host cell fusion. 26 (b) Using single cell RNA sequencing datasets, various human organs have been identified as expressing the target receptors for SARS-CoV-2 infection, ACE2 and TMPRSS2. [28] [29] [30] Subsequently, numerous organoid models have been utilised to detect ACE2 and TMPRSS2. 31 In a study using autopsy tissue samples from patients who had died from Covid-19, SARS-CoV-2 was detected in the lungs, pharynx, brain, heart, liver and kidneys, suggesting viral tropism in these organs. 48 Table 3 . Transcriptomics analysis of infected alveolar organoids 2 days postinfection (dpi) revealed IFN signalling was the most upregulated canonical pathway (pre-print). 50 Similarly, SARS-CoV-2 infection of bronchial organoids induced a moderate increase in type I IFN and IFN-stimulated genes (ISGs) at 5 dpi (pre-print). 33 Note: Table summarising the tropism of different strains of SARS-CoV-2 in various organoid types as well as their ability to support viral replication when specified. Abbreviations: ACE2, angiotensin I converting enzyme 2; hESC, human embryonic stem cells; hPSC, human pluripotent stem cells; iPSC, induced pluripotent stem cells; SARS-CoV-2, severe acute respiratory syndrome related coronavirus-2; SEAM, self-formed ectodermal autonomous multi-zone. Organoid type Table summarising Organoid type Dysregulation of essential cellular proteins and functions during SARS-CoV-2 infection has been reported in a number of models including brain, lung and liver organoids. Cell death was observed in SARS-CoV-2-infected brain 35 and choroid plexus organoids, 34 and an increase in pyknotic cells and cell bursting was observed in infected bronchial organoids (pre-print) 33 and brain spheres, 43 respectively. This has also been observed in influenza A infection, which causes cell death in the respiratory tract and lung parenchyma, which can, in severe cases, result in increased inflammation, a compromised epithelial cell barrier and lung failure. 69 The published studies to date suggest SARS-CoV-2-mediated cell death may contribute to the damage observed clinically in the organs of Covid-19 patients. 70, 71 In brain organoids, SARS-CoV-2-induced phosphorylation and re-localisation of tau (neuronal marker) from the axon of infected neurons to the soma. 35 The tau protein is responsible for stabilising neuronal microtubules and promoting axonal growth. 72 Hyperphosphorylation and abnormal tau aggregation are characteristics of neurodegenerative diseases known as tauopathies such as Alzheimer's disease (AD). [72] [73] [74] In fact, in a three-dimensional brain- The rapid progression and burden of the 90 and Gamaleya (92% efficacy). 91 In tandem with these randomised controlled trials, research using organoid models would provide excellent assistance in the timely evaluation of the safety and efficacy of various treatment options. Lung organoids pre-treated with imatinib, mycophenolic acid (MPA), quinacrine dihydrochloride (QNHC) and chloroquine blocked EGILMEZER AND RAWLINSON -7 luciferase activity following SARS-CoV-2-entry virus infection, suggesting potential efficacy in decreasing SARS-CoV-2 infection. 32 In SARS-CoV-2-infected alveolar organoids, viral nucleoprotein (N) RNA was reduced following the treatment with IFN-β1 (3·2 log), hydroxychloroquine (2·4 log) and remdesivir (9 log) compared to infected, untreated organoids. 50 However, hydroxychloroquine exhibited variable effects on viral replication and gene expression that were dependant on the donor epithelium (pre-print). 50 Pre-treatment of colon organoids with both IFN-β1 and IFN-λ significantly impaired infection and this was associated with a decrease in viral genome copies. 52 Clinical-grade human recombinant soluble ACE2 (hrsACE2) has been tested in phase 1 92 Camostat, a TMPRSS2 inhibitor, is a promising therapeutic candidate for SARS-CoV-2 in Caco-2 and Vero-TMPRSS2 cell culture models. 26 Suzuki et al. reported a reduction of SARS-CoV-2 genome in infected bronchial organoids to 2% of that of infected, untreated organoids (pre-print). 33 Furthermore, camostat treatment suppressed the SARS-CoV-2 mediated increase in genes involved in the immune response (pre-print). 33 Despite the advantages of organoids as an alternative to traditional culture systems, limitations exist in the organoid model. One such limitation is the variability between individual organoids. Little et al. reported transcriptional variability between kidney organoids from different experimental batches, particularly in genes related to temporal maturation. 94 However, other studies have reported little variability in cortical and dorsal forebrain organoids, comparing the variation as being similar to that of endogenous brains. 95, 96 It is important to take into consideration the degree of accuracy to which organoids mimic the cell composition and structure of human organ development. Bhaduri et al. reported smaller numbers of cell subtypes in cortical organoids compared to primary brain tissue, and a portion of organoid cells co-expressed markers for both radial glial and neuronal cells, indicating broader cell type characterisation in organoids. 97 Structurally, the human cortex consists of stratified laminae with distinct neuronal populations; however, cerebral organoids reportedly contain neurons of different layers interspersed throughout the organoid, indicating a lack of stratified organisation. 98 Other studies have, however, reported the development of different brain regions and stratified layers within cerebral organoids. 21, 99 Unlike monocultures which are excellent for large-scale experiments, the time-consuming and technically challenging nature of organoid generation has brought into question the scalability of this alternative model. 14 Equipment such as the mini-bioreactor can improve organoid scalability as it allows for the consistent culture of multiple organoids and larger-scale organoid production that is necessary for applications such as compound testing and drug efficacy investigations. 21 The original source of the cells used to differentiate organoids is an important consideration for future studies. The reviewed SARS-CoV-2 infection studies (Table 1) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Origin and evolution of pathogenic coronaviruses Comparing clinical characteristics of influenza and common coronavirus infections using electronic health records Seasonality of respiratory viral infections Coronavirus infections-more than just the common cold COVID-19: a fast evolving pandemic Clinical Characteristics and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19) Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia A survey of human brain transcriptome diversity at the single cell level Functional organization of the transcriptome in human brain Organoids: a historical perspective of thinking in three dimensions Reciprocal interactions between β1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology Organogenesis in a dish: modeling development and disease using organoid technologies Disease modelling in human organoids The importance of animal models in the development of vaccines ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates Three-dimensional models for studying development and disease: moving on from organisms to organs-on-achip and organoids Russell and Burch's 3Rs then and now: the need for clarity in definition and purpose Human organoids: model systems for human biology and medicine Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure Zika virus infection and microcephaly: evidence regarding geospatial associations COVID-19 and multi-organ response Neurological associations of COVID-19 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart The scRNA-seq expression profiling of the receptor ACE2 and the cellular protease TMPRSS2 reveals human organs susceptible to COVID-19 infection SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes Progenitor identification and SARS-CoV-2 infection in long-term human distal lung organoid cultures Identification of SARS-CoV-2 inhibitors using lung and colonic organoids Generation of human bronchial organoids for SARS-CoV-2 research Human pluripotent stem cell-derived neural cells and brain organoids reveal SARS-CoV-2 neurotropism predominates in choroid plexus epithelium SARS-CoV-2 targets neurons of 3D human brain organoids SARS-CoV-2 infection of ocular cells from human adult donor eyes and hESC-derived eye organoids Infection of bat and human intestinal organoids by SARS-CoV-2 TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 Long term culture of human kidney proximal tubule epithelial cells maintains lineage functions and serves as an ex vivo model for coronavirus associated kidney injury Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2 The development of neural stem cells Differentiation of neural lineage cells from human pluripotent stem cells Coronavirus (COVID-19) infection in pregnancy-information for healthcare professionals SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract Multiorgan and renal tropism of SARS-CoV-2 Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery SARS-CoV-2 productively infects human gut enterocytes Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells Imbalanced host response to SARS-CoV-2 drives development of COVID-19 SARS-CoV-2 infection: the role of cytokines in COVID-19 disease Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Mechanism of inflammatory response in associated comorbidities in COVID-19 Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study Type III interferons in viral infection and antiviral immunity Type 1 interferons and the virus-host relationship: a lesson in detente Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 Activation and evasion of type I interferon responses by SARS-CoV-2 Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice Functional exhaustion of antiviral lymphocytes in COVID-19 patients Human cytomegalovirusinduces cytokine changes in the placenta with implications for adverse pregnancy outcomes The clinical pathology of severe acute respiratory syndrome (SARS): a report from SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases The induction and consequences of Influenza A virus-induced cell death Clinical and pathological investigation of patients with severe COVID-19 Extrapulmonary manifestations of COVID-19 Tau in physiology and pathology Abnormal phosphorylation of the microtubuleassociated protein tau (tau) in Alzheimer cytoskeletal pathology Tau in Alzheimer disease and related tauopathies A 3D human brain-like tissue model of herpes-induced Alzheimer's disease The diverse cellular responses of the choroid plexus during infection of the central nervous system Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus SARS-CoV-2: underestimated damage to nervous system Dysregulated bile transporters and impaired tight junctions during chronic liver injury in mice SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19 Remdesivir for the treatment of Covid-19 -final report Dexamethasone in hospitalized patients with Covid-19 -preliminary report Remdesivir: first approval Dexamethasone for COVID-19? Not so fast Repurposed antiviral drugs for COVID-19 -interim WHO SOLIDARITY trial results Baricitinib plus remdesivir for hospitalized adults with Covid-19 Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine The first interim data analysis of the Sputnik V vaccine against COVID-19 phase III clinical trials in the Russian Federation demonstrated 92% efficacy Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome Evaluation of variability in human kidney organoids Individual brain organoids reproducibly form cell diversity of the human cerebral cortex Reliability of human 3D cortical organoid generation Cell stress in cortical organoids impairs molecular subtype specification Human brain development through the lens of cerebral organoid models Generation of cerebral organoids from human pluripotent stem cells Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models No funding sources to declare. All authors had full access to the manuscript and accept responsibility to submit for publication. We declare no competing interests. William D Rawlinson designed the review, editing and writing throughout the process. Ece Egilmezer reviewed the results of the search strategy, wrote and edited the manuscript. All authors reviewed the manuscript for the final draft. Data sharing not applicable to this article as no datasets were generated or analysed during the current study. https://orcid.org/0000-0001-5926-7082William D Rawlinson https://orcid.org/0000-0003-0988-7827